Diagnostic accuracy of anti-DNase I antibodies measurement in a differentiation between SLE and other autoimmune rheumatic diseases was evaluated. The share of anti-DNase I and actin in the DNase I activity decrease in SLE was established. Serum samples were obtained from 54 patients with verified SLE, 52 control patients with other autoimmune rheumatic diseases, and 44 healthy persons. Anti-DNase I concentrations were measured by ELISA. Free and actin inhibited DNase I activities were evaluated in the fresh serum samples. The appraisal of antibodies and actin effects on DNase I activity was made using multiple regression. Anti-DNase I antibodies were positive in 35 SLE and 8 control patients, without significant difference between the mean antibody concentrations. Sensitivity of this test was 64.81 %, and specificity-84.62 %. Mean free DNase I activity in SLE was somewhat lower than in the control group as a result of augmented frequency of extremely low enzyme activities. On the contrary, after the exclusion of the latter cases we have revealed elevated mean free DNase I activity in the other SLE patients comparing to the similar control subgroup. Unlike the controls, low serum DNase I activity in SLE arose not only from actin and antibody action, but also, in half of the cases, from unidentified factor, related to active SLE. The accuracy of the anti-DNase I antibodies measurement is approximate to the present reference standard of SLE diagnostics. We first demonstrated that neither antibodies nor actin caused DNase I activity decrease in SLE.
На взаимосвязь между ревматическими заболе ваниями и патологией щитовидной железы (ЩЖ) исследователи обратили внимание еще в XIX веке. В 1874 г. W. Gull описал явления мышечной скован ности и припухлости суставов в сочетании с крети ноидным статусом при гипотиреозе (микседеме) у 5 женщин [9]. G. Means с целью уточнения патоге неза поражения суставов и мягких тканей при гипо тиреозе провел ряд исследований на крысах. В ходе эксперимента автор выявил увеличение продукции гиалуроновой кислоты, уменьшение хондроитин сульфата в коже исследуемых крыс [3,10].Особый интерес для исследователей представ ляет органоспецифическая аутоиммунная патология ЩЖ -болезнь Грейвса (БГ) и аутоиммунный тирео идит Хашимото, а также ее возможная взаимосвязь
A relationship is revealed between the level of antibodies to superoxide dismutase and the activity, course, and form of a disease. The production of antibodies to red cell superoxide dismutase increases as the pathological process progresses. By reducing the resistance of erythrocyte membranes to reactive oxygen species, antibodies to red cell superoxide dismutase promote the development of anemia in patients with rheumatoid arthritis. The results indicate that inhibition of the active center of this enzyme by specific immunoglobulins is one of the causes of reduced activity of red cell superoxide dismutase or the lack of an appreciable increase in its activity during hyperproduction of reactive oxygen species.
Objective of study: refining immune diagnostics of systemic scleroderma through determining ceruloplasmin antibodies, its amount and enzymatic activity, as well as control of effectiveness of therapy with ceruloplasmin-based immobilized magnetocontrollable immunosorbents.Materials and methods. 30 apparently healthy individuals and 68 patients with systemic scleroderma were examined. The study included patients with referral diagnosis of systemic scleroderma who signed an informed consent. The study was performed in accordance with the principles of World Medical Association Declaration of Helsinki rev. 2013 (ACR/EULAR). All participants had their blood tested with the method of immunoenzymatic determination of antibodies to ceruloplasmin upon admission to hospital and prior to discharge.Results. It was established that patients with systemic scleroderma show reduced oxidase activity of ceruloplasmin, increased ceruloplasmin levels, as well as elevated antibodies to ceruloplasmin compared with the control group. A link between the amount of antibodies to the studied enzyme, and the activity, nature, course and stage of the disease was established. It was found that there is a reliable negative correlation between the level of ceruloplasmin antibodies, and the amount of RBCs, the hemoglobin level. For the first time a complex assessment of three parameters was employed, the parameters being the enzymatic activity, ceruloplasmin amount, and antibodies to ceruloplasmin. It was established that autoantibodies to ceruloplasmin are more often found in systemic scleroderma patients who show a high disease activity, subacute course with involvement of the liver, lungs, and with anemia. It was found that antibodies to ceruloplasmin are detected at early stages of systemic scleroderma development and can be used in timely diagnosis of the condition. It was shown that the change of parameters under study over time can serve as a basis on which to evaluate the effectiveness of administered therapy.Conclusion. Decreased enzymatic activity of ceruloplasmin, its elevated amount and increased antibodies to ceruloplasmin can be taken as additional diagnostic tools in evaluation of systemic scleroderma activity. These parameters promote a more accurate assessment of the disease activity and of the nature of the pathologic process; they can serve as an indication of a variety of clinical forms of the disease. Employing these parameters for monitoring of administered therapy in hospital settings permits a more accurate assessment of its effectiveness and making adjustments. Studying ceruloplasmin antibody formation, amount of ceruloplasmin and its biochemical activity extends the existing concept of rheumatic disease pathogeny, outlines a way forward for further research and reflects the involvement of antioxidant system in immune disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.